Pentraxin Therapeutics is a UCL spinout company formed in 2001. It holds all the intellectual property and proprietary knowledge emanating from Professor Pepys’ research at UCL. Pentraxin Therapeutics Ltd is concerned with the research and development of drugs for the treatment of amyloidosis and amyloid-related diseases such as Alzheimer’s disease and type 2 diabetes, as well as targeting the pathogenic effects of C-reactive protein in cardiovascular disease and inflammatory diseases.